Tadalafil Tablet, Film Coated
Product Images NDC 63629-8157

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Tadalafil (NDC 63629-8157). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label Image (Lbl636298157)

This is a medication called Tadalafil 10mg, presented in a yellow oval tablet form that is comparable to Cialis. It should be stored at room temperature and kept away from children, and the recommended quantity is 30 tablets. The manufacturer is Sun Pharmaceutical Industries Inc. The other text, "Buyant Ranch Prcpach Bunbank, 04 91508", and "NDC 6362981571 08157301523487" is not clear and may be irrelevant.*

FDA Label Image

Spl-tadalafil-figure-1 (Spl Tadalafil Figure 1)

This appears to be a table or graph showing the differences in blood pressure (systolic and diastolic) between standing and supine positions, with separate columns for the drug Tadalafil compared to a placebo. There is also a time aspect to the data, measured in hours. However, some of the characters are not readable or do not make sense, making it difficult to provide a more detailed description.*

FDA Label Image

Spl-tadalafil-figure-2 (Spl Tadalafil Figure 2)

This appears to be a chart or graph displaying the standing and supine systolic blood pressure (measured in mmHg) over time post-dose in participants taking either Tadalafil 20 mg & doxazosin 8 mg or placebo & doxazosin 8 mg. No additional context or information is available.*

FDA Label Image

Spl-tadalafil-figure-3 (Spl Tadalafil Figure 3)

This is a chart showing different dosages and timings of medications given to patients and their systolic blood pressure readings at varying time intervals after administration. Tadalafil and doxazosin were compared with placebo and doxazosin.*

FDA Label Image

Spl-tadalafil-figure-4 (Spl Tadalafil Figure 4)

This is a graph that shows the concentration of Tadalafil in plasma at different times after it has been administered. The graph shows the concentration levels for a single 20mg dose of Tadalafil, a single 5mg dose and a once-daily dose of 5mg Tadalafil for 5 consecutive days. The concentration is measured in micrograms per liter (ug/L) and time is measured in hours.*

FDA Label Image

Spl-tadalafil-figure-5 (Spl Tadalafil Figure 5)

The text describes the results of a study comparing the effects of tadalafil 5 mg to placebo based on the change from baseline in IPSS total score. The study lasted for an unspecified number of weeks, and the results indicate a statistically significant improvement in IPSS total score with tadalafil compared to placebo (p<0.01). No further information or context is available.*

FDA Label Image

Spl-tadalafil-figure-6 (Spl Tadalafil Figure 6)

This text presents a graph comparing the change from baseline in IPSS (International Prostate Symptom Score) total score between Tadalafil 5mg and placebo over a duration of 12 weeks. The graph shows that Tadalafil 5mg had a statistically significant improvement compared to placebo, as indicated by the asterisk and p-value provided.*

FDA Label Image

Spl-tadalafil-figure-8 (Spl Tadalafil Figure 8)

The text is describing the change from baseline in IPSS total score for Tadalafil 5 mg and Placebo, indicating a statistically significant difference (p<0.01). However, the duration of the treatment weeks is not provided.*

FDA Label Image

Spl-tadalafil-structure (Spl Tadalafil Structure)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.